Evidence map›Paper›PMID 34944809›Full record

ArticleCancers2021

Targeting Cross-Presentation as a Route to Improve the Efficiency of Peptide-Based Cancer Vaccines.

Ben Wylie, Ferrer Ong, Hanane Belhoul-Fakir, Kristin Priebatsch, Heique Bogdawa, Anja Stirnweiss, Paul Watt, Paula Cunningham, Shane R Stone, Jason Waithman

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. TheiScience · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Ben WylieTelethon Kids Institute, The University of Western Australia, Nedlands, WA 6009, Australia.ORCID 0000-0001-8781-8611
Ferrer OngPYC Therapeutics, Harry Perkins Institute, QEII Medical Centre, Nedlands, WA 6009, Australia.
Hanane Belhoul-FakirSchool of Public Health, Faculty of Health Sciences, Curtin University, Bentley, WA 6102, Australia.
Kristin PriebatschExopharm, Melbourne, VIC 3000, Australia.
Heique BogdawaBiocurate, Parkville, VIC 3052, Australia.
Anja StirnweissPYC Therapeutics, Harry Perkins Institute, QEII Medical Centre, Nedlands, WA 6009, Australia.
Paul WattAvicena, West Perth, WA 6005, Australia.
Paula CunninghamPYC Therapeutics, Harry Perkins Institute, QEII Medical Centre, Nedlands, WA 6009, Australia.
Shane R StoneSchool of Agriculture and the Environment, University of Western Australia, Nedlands, WA 6009, Australia.
Jason WaithmanTelethon Kids Institute, The University of Western Australia, Nedlands, WA 6009, Australia.
Harry Perkins Institute of Medical Research · AUThe Kids Research Institute Australia · AUCurtin University · AUParks Victoria · AUThe University of Western Australia · AU

Funding

Brady Cancer Support Foundation N/ACancer Council Western Australia N/A
6 · The paper itself

Abstract

Cross-presenting dendritic cells (DC) offer an attractive target for vaccination due to their unique ability to process exogenous antigens for presentation on MHC class I molecules. Recent reports have established that these DC express unique surface receptors and play a critical role in the initiation of anti-tumor immunity, opening the way for the development of vaccination strategies specifically targeting these cells. This study investigated whether targeting cross-presenting DC by two complementary mechanisms could improve vaccine effectiveness, in both a viral setting and in a murine melanoma model. Our novel vaccine construct contained the XCL1 ligand, to target uptake to XCR1

Indexed as

cancer vaccinecell penetrating peptidecross-presentationdendritic cellimmunotherapymelanomapeptide vaccine

Identifiers

PMID34944809
PMCPMC8699136
OpenAlexW4200199869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.